Latest news and press releases about Chemomab Therapeutics Ltd. (CMMB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24.
Price
| Price | $2.65 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | 2.44 |
| EV / EBITDA | -1.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -70.81% |
| Return on Invested Capital | -91.65% |
| Return on Assets | -74.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BIVI · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of CMMB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks